cgp 42112a has been researched along with pd 98059 in 1 studies
| Studies (cgp 42112a) | Trials (cgp 42112a) | Recent Studies (post-2010) (cgp 42112a) | Studies (pd 98059) | Trials (pd 98059) | Recent Studies (post-2010) (pd 98059) |
|---|---|---|---|---|---|
| 233 | 0 | 35 | 4,939 | 3 | 1,001 |
| Protein | Taxonomy | cgp 42112a (IC50) | pd 98059 (IC50) |
|---|---|---|---|
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 2.8 | |
| Luciferin 4-monooxygenase | Photinus pyralis (common eastern firefly) | 6.3 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 2.8 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 2.8 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Rattus norvegicus (Norway rat) | 4.2 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Rattus norvegicus (Norway rat) | 4.2 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamata, K; Kobayashi, T; Matsumoto, T; Taguchi, K | 1 |
1 other study(ies) available for cgp 42112a and pd 98059
| Article | Year |
|---|---|
Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Activation; Flavonoids; Losartan; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Phosphorylation; Protein Kinase Inhibitors; Receptor, Angiotensin, Type 2; Signal Transduction; Time Factors; Vasodilation; Vasodilator Agents | 2012 |